Aerovate Therapeutics Overview
Aerovate Therapeutics (AVTE) has a ROE of -42.94%, below the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow-42.94%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Aerovate Therapeutics (AVTE) currently reports a ROE of -42.94%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Aerovate Therapeutics's ROE history and peer comparisons.
Aerovate Therapeutics's ROE of -42.94% is lower than the Healthcare sector average of 20.77%. That is roughly 306.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Aerovate Therapeutics's current -42.94% should be judged against Healthcare norms (sector average: 20.77%) and against AVTE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -42.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Aerovate Therapeutics, and consider following AVTE for alerts when major investors trade the stock.
Aerovate Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -42.94% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVTE with unrelated industries.
